logo-loader
viewVolitionRx

VolitionRX brings its Nu.Q cancer-screening platform to China

The company is partnering with Shanghai Fosun Long March Medical Science Co Ltd, a manufacturer of diagnostic and laboratory instruments on a lung cancer study

Shanghai, China
China accounts for 20% of the world's population but 24% of the world's lung cancer diagnoses

VolitionRx Limited (NYSEMKT:VNRX) is bringing its cancer-screening blood tests to China for a new lung cancer study.

The company is partnering with Shanghai Fosun Long March Medical Science Co Ltd, a manufacturer of diagnostic and laboratory instruments. The study will use Volition’s Nu.Q assays to screen for lung cancer at Fosun's hospitals, research institutions and clinics, among other locations.

The two parties previously signed a memorandum of understanding, and the study represents the execution of that contract.

READ: VolitionRx Limited awarded an additional $1.4 million in non-dilutive funding

Nu.Q functions as a routine blood test that looks for molecular signatures of cancer by focusing on the nucleosomes — a section of DNA wrapped around a core of proteins — in the blood. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes..

"The need for a simple, easy to use, cost effective test for cancer is truly universal and we hope very much that our Nu.Q tests can help revolutionize the way cancer is diagnosed worldwide," Volition CEO Cameron Reynolds said.

"We see Asia, and particularly lung cancer in China, as a key market for Volition. We are excited about the commencement of our work in China and look forward to a successful collaboration with Fosun Long March," he added.

According to Fosun chairman Yuejian Zhang, China accounts for 20% of the world's population but 24% of the world's lung cancer diagnoses and 30% of cancer-related deaths. 

Shares in Volition rose 4.2% to $3.50 Thursday morning.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 5.36 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $220.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: VolitionRx achieves 'massive breakthrough' in its Nu.Q...

VolitionRx Limited (NYSEAMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the cancer diagnostic company has achieved a 'massive breakthrough' in the development of its Nu.Q Capture cancer-detection technology, which is the ability to enrich nucleosomes. Reynolds says enriching nucleosomes...

4 weeks ago

2 min read